Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
25.45
+0.12 (0.47%)
Dec 10, 2025, 12:10 PM EST - Market open
Pfizer Revenue
Pfizer had revenue of $16.65B in the quarter ending September 28, 2025, a decrease of -5.92%. This brings the company's revenue in the last twelve months to $62.79B, up 3.89% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63B with 6.84% growth.
Revenue (ttm)
$62.79B
Revenue Growth
+3.89%
P/S Ratio
2.29
Revenue / Employee
$775,123
Employees
81,000
Market Cap
144.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PFE News
- 33 minutes ago - Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports - Reuters
- 3 hours ago - TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer - Business Wire
- 19 hours ago - Down 50%, Should You Buy the Dip on Pfizer? - The Motley Fool
- 20 hours ago - Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill? - Invezz
- 1 day ago - Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill - CNBC
- 1 day ago - Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons - GlobeNewsWire
- 1 day ago - Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains - Seeking Alpha
- 1 day ago - Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500 - Seeking Alpha